Morning Overview on MSN
How science and luck sparked a radical new era in schizophrenia treatment
The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a ...
The US Food and Drug Administration (FDA) is due to issue a decision by September 26 on the approval of KarXT, a potential first-in-class antipsychotic. If approved, it would be the first drug with a ...
The first schizophrenia medication in decades with a new mechanism of action won US regulatory approval today. The approval offers the hope of an antipsychotic that would be more effective and better ...
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the ...
Antipsychotic use in people with dementia is associated with elevated risks of a wide range of serious adverse outcomes including stroke, blood clots, heart attack, heart failure, fracture, pneumonia, ...
The importance of glutamate release modulation by evenamide used as an add-on therapy for patients with schizophrenia inadequately responding to their second-generation antipsychotics, including ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results